A recombinant chimeric antigen constructed with B-cell epitopes from Mycobacterium leprae hypothetical proteins is effective for the diagnosis of leprosy

•B-cell epitopes from specific M. leprae hypothetical proteins were predicted.•They were used to construct a novel recombinant chimeric protein, M1.•M1 antigen was tested in ELISA experiments for the leprosy diagnosis.•High sensitivity and specificity was found to both pauci- and multibacillary form...

Full description

Saved in:
Bibliographic Details
Published inDiagnostic microbiology and infectious disease Vol. 109; no. 3; p. 116338
Main Authors Assis, Bárbara P.N., Chaves, Ana T., Lage, Daniela P., Cardoso, Mariana M., Pereira, Isabela A.G., Câmara, Raquel S.B., Freitas, Camila S., Martins, Vívian T., Ludolf, Fernanda, de Oliveira, Ana Laura G., Oliveira-da-Silva, João A., Tavares, Grasiele S.V., Galdino, Alexsandro S., Chávez-Fumagalli, Miguel A., Machado-de-Ávila, Ricardo A., Christodoulides, Myron, Gonçalves, Denise U., Bueno, Lílian L., Fujiwara, Ricardo T., Coelho, Eduardo A.F., da Costa Rocha, Manoel Otávio
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•B-cell epitopes from specific M. leprae hypothetical proteins were predicted.•They were used to construct a novel recombinant chimeric protein, M1.•M1 antigen was tested in ELISA experiments for the leprosy diagnosis.•High sensitivity and specificity was found to both pauci- and multibacillary forms.•This new antigen could be considered as a candidate for the diagnosis of disease. The diagnosis if leprosy is difficult, as it requires clinical expertise and sensitive laboratory tests. In this study, we develop a serological test for leprosy by using bioinformatics tools to identify specific B-cell epitopes from Mycobacterium leprae hypothetical proteins, which were used to construct a recombinant chimeric protein, M1. The synthetic peptides were obtained and showed good reactivity to detect leprosy patients, although the M1 chimera have showed sensitivity (Se) and specificity (Sp) values higher than 90.0% to diagnose both paucibacillary (PB) and multibacillary (MB) leprosy patients, but not those developing tegumentary or visceral leishmaniasis, tuberculosis, Chagas disease, malaria, histoplasmosis and aspergillosis, in ELISA experiments. Using sera from household contacts, values for Se and Sp were 100% and 65.3%, respectively. In conclusion, our proof-of-concept study has generated data that suggest that a new recombinant protein could be developed into a diagnostic antigen for leprosy. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0732-8893
1879-0070
DOI:10.1016/j.diagmicrobio.2024.116338